Allergan Aesthetics Commercial Advisory Board Meeting_Evaluation

Skip to the content

Allergan Aesthetics Commercial Advisory Board — Pre-Meeting Questionnaire

Full name *

1. What percentage of your total filler patients receive HA fillers (across all facial areas and indications)? *

<25%
25–50%
51–75%
>75%

2. Of your HA filler patients, what percentage are treated with Juvéderm products? *

<25%
25–50%
51–75%
>75%

3. How has the proportion of HA filler use changed in your overall injectable treatments over the past 2–3 years? *

Increased significantly
Increased moderately
Stayed the same
Decreased slightly
Decreased significantly

4. What are the primary treatment goals your patients express when seeking injectable fillers? *

Lifting
Contouring
Rejuvenation
Slimming
Skin quality
Skin tightening
Other (Please specify)

4. Other (Please specify) *

5. What attributes of HA fillers matter most to your patients? *

Minimal downtime
Natural-looking results
Immediate results
Other (Please specify)

5. Other (Please specify) *

6. What concerns (if any) do patients raise when considering HA fillers? *

Safety
Downtime
Fear of unnatural results
Being unsatisfied with the results
Price
Longevity
Other (Please specify)

6. Other (Please specify) *

7. How do you typically address or manage these patient concerns during consultation? (e.g., specific communication strategies, clinical tools, before-and-after images, educational materials) *

8. What are your key considerations when selecting between HA filler brands? *

Safety profile and clinical data
Rheological properties (e.g., G’, cohesivity, elasticity)
Longevity and durability of results
Natural-looking aesthetic outcomes
Range of indications and product versatility
Patient preference or past experience
Ease of injection or handling characteristics
Risk of complications
Price and cost-effectiveness
Brand reputation and scientific support
Other (Please specify)

8. Other (Please specify) *

9. Which benefits of HA fillers do you believe are under-recognised or under-leveraged? *

Reversibility and safety profile
Hydration and skin quality benefits
Immediate visible results
Versatility across treatment areas
Suitability for younger/prejuvenation patients
Integration to combination treatment protocols
Structural support
Natural-looking outcomes
Strong lifting/shaping capability
Other (Please specify)

9. Other (Please specify) *

10. In your clinical experience, what are the most significant limitations of HA fillers including Juvéderm products? *

Short duration of effect
Risk of overfilling/”pillow face”
Limited collagen stimulation
Lack distinctiveness in the market
Other (Please specify)

10. Other (Please specify) *

11. How do you perceive Juvéderm Hylacross products compared with other mid-range HA fillers (e.g., in terms of clinical performance and patient outcomes)? *

Much better
Slightly better
About the same
Slightly worse
Much worse

12. How do you perceive Juvéderm Vycross products compared with other premium-range HA fillers (e.g., in terms of clinical performance and patient outcomes? *

Much better
Slightly better
About the same
Slightly worse
Much worse

13. Please elaborate on your answers to Questions 11 and 12 *

14. How do you perceive the role of HA fillers relative to other injectable technology such as biostimulators? *

HA remains highly valuable
HA and other injectables have distinct roles
HA is becoming outdated
HA and other injectables are complementary
Biostimulators are the future
Others (Please specify)

14. Other (Please specify) *

15. What factors are driving increased clinical and patient interest in biostimulators? *

Longevity
More natural-looking results
Skin quality improvements
Innovation appeal
Peer influence
Patient demand
Others (Please specify)

15. Other (Please specify) *

16. What are your key considerations when choosing between HA fillers and other injectable technology? *

17. What proportion of your HA filler treatments are combined with other (non-HA) filler types? *

<25%
25–50%
51–75%
>75%

of of 13.

18. What proportion of patients do you combine HA fillers with other non-surgical aesthetic treatments (e.g., botulinum toxin, biostimulators, RF, exosomes, EBDs, polynucleotides?) *

<25%
25–50%
51–75%
>75%

19. In which patient types or clinical scenarios do you see the greatest benefit from a multimodal treatment approach? *

20. How do your patients typically respond when multimodal treatment plans are proposed? *

Very open and receptive
Generally open but need more education
Sometimes resistant or hesitant
Frequently resistant or hesitant
Others (Please specify)

20. Other (Please specify) *

21. What are the most common concerns patients raise about multimodal treatment plans? *

Cost
Safety
Fear of looking unnatural
Treatment fatigue or overwhelm
Lack of understanding of benefits
Time commitment or downtime
Others (Please specify)

21. Other (Please specify) *

22. As a clinician, what additional support would help you promote multimodal aesthetic treatment more effectively to your patients? *

Patient education materials (e.g., brochures, videos)
Evidence-based outcomes or clinical data
Treatment decision tree with sequence recommendation and scientific rationale
Localised before-and-after images
Training on how to communicate the value of combined approaches
Tools to explain costs and package treatment plans
Others (Please specify)

22. Other (Please specify) *

23. Are global campaigns such as the AA Signature initiative currently well-aligned with the needs of Asian patients in your practice? *

Yes
Somewhat
No
Not familiar with the campaign

24. What specific aspects of the AA Signature initiative would you recommend adapting to better align with the needs and preferences of your local market? *

25. How would you rate the quality of Allergan Medical Institute (AMI) events you’ve attended over the past 3 years, relative to other training or scientific programs? *

Very poor
Below average
Average
Good
Excellent

26. What improvements or additions would you like to see in future AMI events to enhance their educational value or relevance to your clinical practice? *

Meeting organized and funded by Allergan Aesthetics, an AbbVie company. For healthcare professional only.
Suite 2404, 24/F, AIA Tower, 183 Electric Road, North Point, Hong Kong
Tel: (852) 2610 2525
Veeva PromoMat Code: HK-AGNA-250035 | Date of Approval: 23 June 2025